Pharmacokinetics of Coencapsulated Antiretrovirals with Ingestible Sensors

Honghu Liu,^{1–3} Eric Daar,⁴ Yan Wang,^{3,5} Lisa Siqueiros,⁴ Kayla Campbell,⁶ Jie Shen,¹ Mario Guerrero,⁴ Meng-Wei Ko,⁷ Di Xiong,³ John Dao,⁸ Todd Young,⁸ Marc Rosen,⁹ and Courtney V. Fletcher⁶

Abstract

We investigated the use of a system with an ingestible sensor (Proteus Digital Health Feedback system) coencapsulated with antiretrovirals (ARVs) to measure real-time adherence. To assess the safety and impact, if any, coencapsulation might have on ARV concentrations, we evaluated the pharmacokinetics of ARVs coencapsulated with an ingestible sensor for eight commonly used fixed-dose combination ARVs: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF); FTC/tenofovir alafenamide (TAF); efavirenz (EFV)/FTC/TDF; abacavir (ABC)/lamivudine (3TC); dolutegravir (DTG)/ABC/3TC; rilpivirine (RPV)/TAF/FTC; elvitegravir (EVG)/cobicistat (COBI)/FTC/TAF; and bictegravir (BIC)/FTC/TAF. The steady-state apparent peak plasma concentration (C_{max}) and area under the concentration-time curve (AUC) were determined from plasma concentrations measured at predose, 1, 2, 4, and 6 h postdose, and compared with literature values. A total of 49 unique patients on stable regimens for at least 12 weeks with undetectable viral loads were recruited. C_{max} and AUC values were not statistically significantly different from literature values for all of the formulations except the C_{max} of FTC/TDF, C_{max} of BIC, and the C_{max} of RPV. In a subsequent evaluation of FTC/TDF and BIC/FTC/TAF using a crossover design, the geometric mean ratio (GMR) between the coencapsulated and the unencapsulated formulations for FTC/TDF were the following: FTC, 84.6% (90% confidence interval [CI] 66.6–107.4) for AUC and 77.5% (60.1–99.9) for C_{max}. For tenofovir (TFV), the GMR was 96.2% (90% CI 89.2–103.8) for AUC and 87.3% (64.2–118.7) for C_{max}. The GMR for BIC (from the BIC/FTC/TAF formulation) was 98.0% (90% CI 84.5–113.5) for AUC and 89.9% (84.5–95.7) for C_{max}. The observed deviation in FTC/TDF (Truvada) may be due to participant characteristics, fasted/fed conditions, and/or random variation and may warrant further investigations with a larger sample size. These findings provide assurance for use of coencapsulated ARVs for future HIV treatment-adherence research.

Keywords: antiretroviral medication, bioavailability, pharmacokinetics, coencapsulated ARV, ingestible sensor, adherence

Introduction

OBJECTIVE AND ACCURATE measurement of adherence to medication is critical for an understanding of the safety and efficacy of drugs.¹ Traditional measures of adherence, such as pharmacy refill records, pill counts, and medication event monitoring system,^{2–4} provide only inferred measures of actual drug intake and most of them offer no real-time

notification capability. Biosensor and digital medicine has created a new era in medical treatment and public health.^{5–9} The Food and Drug Administration (FDA) approved the first digital medication in 2017⁸ with a biosensor embedded with the medication to record the time medication was taken (Abilify MyCite®), although the ingestible sensor (Proteus) was approved for marketing as a medical device in 2012.¹⁰ This allows the opportunity to provide immediate feedback

¹Division of Public Health and Community Dentistry, University of California, Los Angeles (UCLA), Los Angeles, California.

²Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California.

³Department of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles, California.

⁴Department of Medicine, Division of HIV Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.

⁵Urban Health Collaborative, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania.

⁶Center for Drug Discovery, University of Nebraska Medical Center, Omaha, Nebraska.

⁷Division of Oral Biology and Medicine, School of Dentistry, UCLA, Los Angeles, California.

⁸Proteus Digital Health, Redwood City, California.

⁹School of Medicine, Yale University, New Haven, Connecticut.

in the event of missed doses and improve medication adherence.¹¹

The ingestible sensor has been developed with elements that are consumed in the human diet from dietary minerals: copper, magnesium, and silicon in minute quantities.¹² Research has already demonstrated that the ingestible sensor has no risk of mechanical injury or toxicology concern.^{7,11,13} The ingestible sensor technology has been used in monitoring different diseases such as diabetes,¹⁴ hypertension,¹⁵ mental health disorder,¹⁶ and tuberculosis^{13,17} as well as care for kidney transplant patients,^{11,13,17–20} and has been well-accepted.^{21,22}

To use the ingestible sensor to monitor medication taking and measure adherence, the medication must be coencapsulated with the sensor. There is limited research to date about using an ingestible sensor monitoring system for measuring and monitoring adherence to antiretroviral (ARV) drugs in HIV/AIDS research and treatment. Higher levels of adherence to ARVs are associated with better viral suppression and prevention of resistance and disease progression.²³ Currently, the Proteus Discover® system (Proteus Digital Health Feedback, Redwood City, CA) is the only system that is FDA-approved for safety and also met European Union safety requirements.²⁰ The system includes an ingestible sensor for ingestible event marker and the wearable sensor (patch with a microchip and a tiny battery). The ingestible sensor is activated by gastric fluid and is sensed by the adhesive sensor patch that is placed on the torso and replaced weekly.²⁴ A Bluetooth signal is sent to the patient's mobile device (tablet or smartphone) and then an encrypted message is sent to the central server with all of the transmitted data. Hence, a real-time signal is received once the medication has been taken by the patient.

The objective of this study was to confirm that coencapsulation does not affect the pharmacokinetics (PK) of eight commonly used ARV fixed dose combination tablets. All these ARVs are well absorbed across a spectrum of HIV-infected people ranging from otherwise healthy to those with more advanced coinfections. Some of these ARVs, such as elvitegravir (EVG) and rilpivirine (RPV) are recommended to be given with food. We therefore hypothesized that coencapsulation would not negatively affect the PK parameters of the ARVs, as primarily assessed by maximum concentration (C_{max}) and the 24-h area under the concentration-time curve (AUC) in plasma.

Materials and Methods

In this PK trial, we recruited six HIV-infected individuals for each of the ARV formulations to be tested. All participants were at least 18 years of age and were on a stable ARV regimen with no detectable plasma HIV RNA levels for at least the last 3 months. All the participants indicated the ability to take coencapsulated ARVs at the time of screening and were able to provide informed consent. In addition, participants were required to have either >90% self-reported adherence or be estimated as having a similar level of adherence by their medical providers, to meet the assumption of steady state conditions.

Based on findings that bioavailability was not affected by the ingestible sensor system in other studies, we did not expect to observe a difference with the coencapsulation of

ARVs.^{24–26} Therefore, rather than a classical bioequivalence crossover design with participants serving as their own controls, we performed a PK study that compared the PK parameters of each of the coencapsulated ARVs to those reported in the manufacturer's package insert (or other published literature if necessary). If we observed a significant deviation in this comparison, then a repeat PK study with crossover design was conducted.

The eight commonly used fixed-dose combination ARV tablets studied included the following: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF); FTC/tenofovir alafenamide (TAF); efavirenz (EFV)/FTC/TDF; abacavir (ABC)/lamivudine (3TC); ABC/3TC/dolutegravir (DTG); TAF/FTC/RPV; EVG/cobicistat (COBI)/FTC/TAF; and bictegravir (BIC)/FTC/TAF. Coencapsulation was performed by pharmacists in the Investigational Drug Pharmacy using an appropriately sized capsule (Capsugel®, Greenwood, SC) in manner consistent with guidelines from the sensor manufacturer and as summarized by Browne *et al.* (26). All participants came to the clinic after an overnight fast to take the coencapsulated ARV at the clinic in the morning. After a predose blood draw, they were witnessed to take the coencapsulated ARV medications with breakfast provided 5–20 min after medication. The breakfast consisted of the same food for each participant unless they had a special diet (e.g., diabetes, vegetarian). Another four blood samples were obtained at 1, 2, 4, and 6 h postdose.

This sampling and PK analysis strategy was designed to make it feasible for the study participants, persons living with HIV-infection, to complete the study in the course of a single, ~6-h study visit; to capture C_{max} that ranges from 1 to 5 h for these ARVs formulations in the literature; and to obtain an estimate of elimination half-life. Plasma was shipped from the Harbor-University of California at Los Angeles Medical Center to the Antiviral Pharmacology Laboratory (APL) at the University of Nebraska Medical Center (UNMC) once all six patients for a given formulation completed the trial. ARV concentrations were quantified with validated, quality-controlled, published liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods. C_{max} was taken as the maximum observed plasma concentration. AUC was determined by the linear up/log down trapezoidal method (Phoenix WinNonlin; Certara²⁷) taking the predose concentration to be the 24 h postdose concentration under the assumption of steady-state PK and the principle of superposition.

We used package insert values (transformed data summary information in Table 2) for each ARV drug as reference to conduct a one-sided independent two-sample *t*-test.^{28–30} We did not expect that coencapsulation will reduce C_{max} and/or AUC of the ARV formulations, therefore did not design the study to assess whether coencapsulation would increase C_{max} or AUC. Given this situation, a one-sided *t*-test, rather than a two-sided *t*-test, was selected, and it gave us stronger power to detect any potential difference. The null hypothesis was that the mean values of C_{max} or AUC from coencapsulated ARVs were equal to the reference values for each component of the selected ARV formulations, and the alternative hypothesis was that the mean values of C_{max} or AUC from coencapsulated ARVs were smaller than referenced ARVs at the significant level of 0.05.^{31,32}

As described in the results, a significant difference was found for the C_{max} of FTC and tenofovir (TFV) of coencapsulated

FTC/TDF, and for the C_{max} of BIC of coencapsulated BIC/FTC/TAF when compared with the package insert values. Thus, a classical crossover trial was conducted with six participants for each of FTC/TDF and BIC/FTC/TAF. Participants in this crossover trial had similar inclusion criteria as the main study described above. In the crossover trial, participants, who had been on the above ARVs for at least 12 weeks, came in for a baseline PK blood draw. Participants had their blood drawn predose, took a regular dose of ARVs (i.e., without overencapsulation), and then had their blood drawn at 1, 2, 4, and 6 h postdose. Within 1 week of the first visit, the participants came back for a second PK-blood draw where they had their blood drawn predose, took a dose of coencapsulated ARVs, and then had their blood drawn at 1, 2, 4, and 6 h postdose. PK parameters were calculated as described. The geometric mean ratios (GMRs) of C_{max} and AUC (coencapsulated to not-encapsulated) were calculated and a non-significant difference was defined as the 90% confidence interval (CI) of each ratio being within 80%–125%.

Results

A total of 49 unique participants (6 patients for each of the 8 ARV formulations, 2 patients were taking both Truvada and Descovy or Odefsey, 3 new participants were recruited for the FTC/TDF crossover trial, and for the crossover BIC/FTC/TFV trial, 4 were from the original Biktarvy PK trial and 2 switched from Atripla to Biktarvy) were recruited from the Harbor-UCLA Medical Center. A majority of the patients were males (92%) and half of the patients were Latinos (50%). The mean age ranged from 46 to 56 years across the eight ARV formulations. The overall mean body mass index was 30.4 (standard deviation [SD] 4.57), ranging from 26.5 (SD 5.0) of Atripla to 35.3 (SD 10.1) of Triumeq. Table 1 shows the demographic information for these 48 subjects in PK study and 12 patients in crossover trial. Concomitant medications are shown in Supplementary Table S1.

Table 2 gives the AUC and C_{max} (mean and SD) for each component of the coencapsulated ARVs evaluated in this study. In addition, detailed information on the reference values for each of the eight formulations, including the sample size, mean and SD values of AUC and C_{max} for each component of the ARVs with fasted or fed information, and website links of the online references for each package insert/reference values are also listed in Table 2. If the coefficient of variation (CV) was reported for the reference values, it was converted to SD by multiplying the CV by the mean.

The comparisons of AUC and C_{max} between the averaged values from the six participants and the reference values are listed in Table 3. The one-sided *t*-test for the independent two-sample *t*-test with specific *p* value for each of the ARV component is presented and the significance level 0.05 is used to determine statistical significance. The degrees of freedom vary across different ARVs because different sample sizes were used in the package inserts. The *p* values of the *t*-tests indicated whether the coencapsulated formulation and reference formulation are similar. All *p* values were greater than .05, except for C_{max} of RPV in the RPV/FTC/TAF formulation (*p* = .01), the C_{max} of FTC and TFV from FTC/TDF (*p* = .03 and .01, respectively, for C_{max}), and the C_{max} of BIC in the BIC/FTC/TAF formulation (*p* = .04). The

TABLE 1. CHARACTERISTICS OF PATIENTS

ARVs	Male	Female	NH White	NH AA	Hispanic	Asian	Other	Age (mean ± SD)	BMI (mean ± SD)
TDF/FTC/EFV (Atripla)	6	0	1	2	2	1	0	56 ± 7	26.5 ± 4.96
FTC/TDF (Truvada)	6	0	0	2	4	0	0	50 ± 9	34.2 ± 11.21
FTC/TAF (Descovy)	5	1	0	3	3	0	0	47 ± 10	29.6 ± 8.52
FTC/RPV/TAF (Odefsey)	6	0	0	2	4	0	0	46 ± 7	27.2 ± 2.87
EVG/COBI/FTC/TAF (Genvoya)	5	1	0	2	4	0	0	48 ± 15	30.1 ± 4.64
ABC/3TC (Epzicom)	5	1	1	4	1	0	0	54 ± 9	30.5 ± 9.33
ABC/3TC/DTG (Triumeq)	5	1	1	2	3	0	0	53 ± 10	35.3 ± 10.09
BIC/FTC/TAF (Biktarvy)	6	0	0	2	3	1	0	46 ± 12	30.1 ± 4.14
Summary (N = 48) ^a	44	4	3	19	24	2	0	50 ± 10	30.4 ± 7.57
FTC/TDF (Truvada)—crossover ^b	6	0	0	4	2	0	0	52 ± 5	28.5 ± 3.82
BIC/FTC/TAF (Biktarvy)—crossover ^c	6	0	1	1	3	0	1	50 ± 12	27.0 ± 3.03
Summary (N = 12)	12	0	1	5	5	0	1	51 ± 9	29.3 ± 7.27

^aWe actually only have a total 46 unique patients since two patients were taking both Truvada and Descovy or Odefsey.

^bIn crossover design of Truvada, three patients are newly recruited.

^cNo new patients are recruited in crossover design of Biktarvy, two patients switched from Atripla to Biktarvy.

ABC, abacavir; ARV, antiretroviral; BIC, bictegravir; BMI, body mass index; COBI, cobicistat; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; FTC, emtricitabine; RPV, rilpivirine; 3TC, lamivudine; SD, standard deviation; TAF, tenofovir disoproxil fumarate; TDF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

TABLE 2. REFERENCE ANTIRETROVIRALS AND COMPONENTS FROM PACKAGE INSERTED VALUE

Drug	ARVs	Fasted/Fed	Component	Observed data				Package insert values				References		
				AUC (ng × h/mL)		Cmax (ng/mL)		AUC (ng × h/mL)		Cmax (ng/mL)				
				N	Mean	SD	Mean	SD	N	Mean	SD		Mean	SD
Atripla	Fasted		EFV	6	106812	67219.3	6027.17	3149.23	35	58085	23044	4072	1168	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021937s007lbl.pdf
			FTC	6	11024.8	1791.08	1467.33	423.52	35	10000	3100	1800	700	
			TFV	6	3134.33	1385.68	299.98	55.34	35	2287	685	296	90	
Descovy	Fed		FTC	6	13680.7	4025.29	2238.67	689.86	48	11700	1940	2100	424	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208215s000lbl.pdf
			TFV	6	725.5	409.91	41.06	18.51	48	290	79.5	20	5.22	
Epzicom	Fasted		3TC	6	16092.2	4163.02	1851.5	242.15	11	8870	1830	2040	540	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021652s015lbl.pdf
			ABC	6	15173.8	3994.94	3972.67	2090.93	11	11950	2510	4260	1190	
Genvoya	Fed		COB	6	11173.7	5019.85	1721.28	672.1	19	9500	3220.5	1500	426	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207561s002lbl.pdf
			EVG	6	17216.8	5343.2	1562.67	449.78	19	22800	7910	2100	707.7	
			FTC	6	11976.8	4703.11	1918.67	372.15	19	11700	1942.2	2100	424.2	
			TFV	6	290	123.99	18.67	7.97	19	290	79.46	20	5.22	
Odefsey	Fed		FTC	6	11221.3	4106.61	1890	546.5	19	11700	1942	2100	424.2	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208351s000lbl.pdf
			RPV ^a	6	2779.33	1206.04	145.17	63.62	19	3238	941.5	211.5	54.69	
			TFV	6	261.5	82.49	17.11	3.46	19	290	79.46	20	5.22	
Triumeq	Fasted		3TC	6	15905	4799.11	1902.67	412.37	11	8870	1830	2040	540	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205551s000lbl.pdf
			ABC	6	12363.5	2685.53	3352.83	1661.73	11	11950	2510	4260	1190	
			DTG	6	50384.8	14959.3	3650.17	847.84	11	53600	14472	3670	734	
Truvada	Fasted		FTC	6	9285.67	1561.09	1228.85	281.39	39	10000	3120	1800	720	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021752s047lbl.pdf
			TFV	6	2217.83	510.66	193.97	85.3	39	2287	690	296	90	
Biktarvy	Fasted Fed		BIC ^b	6	54831.67	21939.34	4292.83	1443	4	87538	28625	6080	1325	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf
			FTC	6	10812.33	3009.67	1898.88	645.61	19	11700	1942.2	2100	424.2	
			TAF	6	242.5	214	18.52	12.87	19	290	79.46	20	5.22	

^aWe also compare the RPV with the most updated published results, Kakuda *et al.*³³^bReference for Biktarvy: Gallant *et al.*⁴³

AUC, area under the concentration-time curve; TFV, tenofovir.

TABLE 3. TWO SAMPLE ONE-SIDED T-TEST ON AUC AND C_{MAX}

ARVs		AUC			C _{max}		
Drug	Component	T-stats	DF	p	T-stats	DF	p
Atripla	EFV	3.42	39	1.00	2.82	39	1.00
	FTC	0.78	39	.78	-1.12	39	.13
	TFV	2.37	39	.99	0.10	39	.54
Descovy	FTC	2.05	52	.98	0.70	52	.76
	TFV	6.80	52	1.00	6.41	52	1.00
Epzicom	3TC	5.03	15	1.00	-0.80	15	.22
	ABC	2.06	15	.97	-0.37	15	.36
Genvoya	COB	0.97	23	.83	0.96	23	.83
	EVG	-1.61	23	.06	-1.74	23	.05
	FTC	0.21	23	.58	-0.94	23	.18
	TFV	0.00	23	.50	-0.48	23	.32
Odefsey	FTC	-0.40	23	.35	-0.99	23	.17
	RPV	-0.97	23	.17	-2.43	20	.01
	TFV	-0.76	23	.23	-1.26	23	.11
Triumeq	3TC	4.40	15	1.00	-0.54	15	.30
	ABC	0.32	15	.62	-1.31	15	.11
	DTG	-0.43	15	.34	-0.05	15	.48
Truvada	FTC	-0.55	43	.29	-1.91	43	.03
	TFV	-0.23	43	.41	-2.60	43	.01
Biktarvy	BIC	4.69	8	1.00	-1.98	8	.04
	FTC	-0.85	23	.20	-0.89	23	.19
	TFV	-0.83	23	.21	-0.42	23	.34

Bold figures are statistically significant.

AUC, area under the concentration-time curve; DF, degrees of freedom.

comparison of EVG from the EVG/COBI/FTC/TAF formulation showed marginal differences compared with literature values in C_{max} ($p = .05$) and AUC ($p = .06$). The C_{max} and AUC values for the other four coencapsulated combination tablets were comparable with those published package insert and/or literature values, including EFV/FTC/TDF where no difference for any component was seen.

Based upon results described above, crossover trials were conducted for the FTC/TDF tablet and BIC/FTC/TAF tablet. In the crossover analysis, the GMR of the coencapsulated to not-encapsulated formulations of TFV (in the FTC/TDF formulation) was 96.2% (90% CI 89.2–103.8) for AUC and 87.3% (64.2–118.7) for C_{max}. The GMR for FTC was 84.6% (90% CI 66.6–107.4) for AUC and 77.5% (60.1–99.9) for C_{max}. Thus, the coencapsulated formulation of FTC/TDF did not meet the bioequivalence criteria. The plots of concentration curves for FTC/TDF are shown in Figures 1 and 2. The GMR for BIC was 98.0% (90% CI 84.5–113.5) for AUC and 89.9% (84.5–95.7) for C_{max}, which indicates that BIC in the crossover trial did meet the bioequivalence definition, as did FTC and TAF from the BIC/FTC/TAF formulation. The plots of the concentration curves for BIC/FTC/TAF formulation are shown in Figures 3–5.

Discussion

The PK characteristics of the coencapsulated commercial combination ARV tablets, EFV/TDF/FTC, FTC/TAF, ABC/3TC, and ABC/3TC/DTG (four of the eight evaluated), were comparable with historical data taken from the package inserts or the literature. There was evidence for a marginal influence of coencapsulation (an approximate 25% reduction) on the AUC and C_{max} of the EVG component EVG/COBI/FTC/TAF. Due to a lack of stated package insert values for the C_{max} of RPV, we compared both the AUC and C_{max} with published literature values.³³ There was no significant difference in the AUC of RPV with the reference value, but C_{max} of RPV was significantly different; the AUC and C_{max} of the FTC and TAF components of the RPV/FTC/TAF coencapsulated tablet were not different from package insert values. When compared in a crossover design, we found that coencapsulation of FTC/TDF tablet reduced the C_{max} of both TFV and FTC and the AUC of FTC. The C_{max} of BIC (from the BIC/FTC/TAF tablet) was significantly different when compared with historical values;

FIG. 1. Mean concentration-time curves for emtricitabine (FTC) in Truvada.

FIG. 2. Mean concentration-time curves for tenofovir (TFV) in Truvada.

however, in the crossover trial, the C_{max} and AUC of BIC, FTC, and TFV (from TAF) met the bioequivalence criteria.

In literature, there are two different capsules commonly used for coencapsulation, plant-derived polymer hydroxypropyl methylcellulose and hard gelatin capsules.³⁴ Prior studies indicated comparable bioavailability for both of the two capsules when used for overencapsulation. The drug release and absorption from the two capsules meet the PK criteria for bioequivalence. However, there is at least one study that found that the encapsulation process affected the bioavailability of sumatriptan, a drug used for migraine treatment.³⁵ Encapsulation was shown to delay sumatriptan

absorption about 0–2 h and to reduce the AUC by 21%–27% in healthy volunteers and patients suffering a migraine.

We used the common level of 0.05 as significance level for our two-sample one-sided *t*-test when comparing with historical data. For one-sided *t*-test (which has a larger power compared with a two-sided test for the same data), our approach is quite conservative and tends to identify significant differences when it could not be significantly different otherwise. The purpose of this study was to evaluate the PK of eight commonly used ARVs when coencapsulated with the Proteus sensor and to compare those values with historical data. Our objective was to make sure that the process of

FIG. 3. Mean concentration-time curves for bictegravir (BIC) in Biktarvy.

FIG. 4. Mean concentration-time curves for emtricitabine (FTC) in Biktarvy.

coencapsulation did not result in a clinically significant reduction in concentrations, assessed by C_{max} and AUC. Although it is theoretically possible that coencapsulation could increase C_{max} and AUC, our objective was not to assess such a change or to determine the exact mechanism of any reduction observed. Thus, we use one-sided *t*-test to test if there is a negative effect of coencapsulation on C_{max} and AUC.

The mechanism for the reduction in EVG C_{max} and AUC by over encapsulation, although the test effect is marginal, is not known. A food effect may have contributed, as participants were given the coencapsulated ARV medications in the fasting state with breakfast provided 5–20 min after medication was taken. Food significantly enhances the oral bio-

availability of EVG and forms the basis for the clinical recommendation that EVG be taken with food. The AUC of EVG can be decreased by up to 50% when taken on an empty stomach compared with food.³⁶ The small delay in the administration of food until after EVG was taken might have been sufficient to cause the reduction in C_{max} and AUC. We believe the magnitude of the reduction seen (in comparison with historical average PK parameters where it was given with food although timing was not specified) is unlikely to be clinically significant. For example, coadministration of antacids 2 h after EVG (Genvoya tablet) reduces EVG C_{max} and AUC ~20% and that reduction is considered clinically acceptable.³⁷ Similarly, the cause of the reduced C_{max}, but not

FIG. 5. Mean concentration-time curves for tenofovir (TFV) in Biktarvy.

AUC, for RPV in the RPV/FTC/TAF coencapsulated tablet is not known, but it is also most likely related to differences in the meals provided. RPV absorption is highly sensitive to the effect of food; exposure is reduced by 40% when taken in a fasted state (vs. a normal or high caloric meal) and this forms the basis for the recommendation that RPV be taken with a meal. As overall exposure (i.e., AUC) was not reduced, the reduction in RPV C_{max}, if not due to the effect of a difference in meals between our study and the reference study, is unlikely to be clinically significant. For both EVG/COBI/FTC/TAF and RPV/FTC/TAF, it is noted that none of the other ARVs (FTC and TAF) was affected by coencapsulation, indicating the reduction observed for EVG and RPV is not a uniform effect on all components of their respective fixed dose tablets.

Coencapsulation reduced the C_{max} of FTC and TDF and the AUC of FTC by 15%–22%; the mechanism of this reduction is not known. Our results are in contrast to those reported in a bioequivalence study of FTC/TDF conducted in 24 healthy subjects who received a single dose of FTC/TDF unencapsulated and coencapsulated with the same ingestible sensor (Proteus) and empty capsules (Capsugel DBCaps) used in our study.²⁴ That study and a recently published study found that the C_{max} and AUC values for TFV and FTC were completely within the standard bioequivalence definition; a recently published bioequivalence evaluation in healthy-volunteers of TDF given as TDF/FTC/RPV coencapsulated with a different sensor also found bioequivalence for TDF.^{24,38} There are some important differences between the Ibrahim and Chai studies and our present evaluation. The studies by Ibrahim and Chai enrolled healthy volunteers, while our study enrolled HIV-infected persons; PK differences have been observed between healthy volunteers and HIV-infected persons.^{24,39} Ibrahim enrolled 24 participants and Chai enrolled 10 participants versus ours of 6. Ibrahim used a more complete sampling of the concentration-time curve by giving a single dose and collecting samples out to 72 h postdose; drug administration was in the fasting state and subjects remained fasting for 4 h after administration. In contrast, our study was conducted at steady-state, used more limited sample collection, could only collect blood samples within the 24 h of the once-daily dosing regimen for HIV-infected persons, and while drug administration was in the fasting state, a breakfast was given 5–20 min after administration. Thus, there are several potentially relevant differences that could account for the difference in results between our study and that of Ibrahim *et al.* Regardless, the magnitude of the difference in PK characteristics was small with the reduction in C_{max} for TFV and FTC being 13% and 22%, respectively; the reduction in the AUC of FTC was only 15% (with a *p* value of .29 from one-sided two-sample *t*-test). We did not measure the pharmacologically active intracellular moieties of TFV and FTC (TFV-diphosphate and FTC-triphosphate) and thus do not know whether these reductions in plasma concentration translate into reductions in intracellular concentrations. We cannot exclude the possibility that these reductions in plasma concentrations are clinically significant. We believe that the most likely explanations for the difference between the Ibrahim study and ours are the difference in subjects (healthy volunteers vs. HIV-infected persons) and/or the difference in meal administration. For our subsequent studies in HIV-infected persons, we have modified

our procedures to give coencapsulated FTC/TDF in the fasting state (as in the current study) and to maintain that fasting state for 2 h following drug administration.

We acknowledge certain limitations of our study design. We used a sparse sampling strategy designed to accommodate the PK evaluations to be conducted in these persons living with HIV-infection in the course of an approximate 6-h study visit. In this design, we used the predose concentration (obtained ~24 h before the dose given at the study visit) to represent the 24-h concentration following the observed dose at the study visit. This is a valid approach under the assumption of steady-state PK conditions. Our entry criteria, described in Methods, were designed to enroll persons stable on their ART regimen who were highly adherent. Although we hypothesized that coencapsulation would not affect C_{max} or AUC, we reasoned that if there was an effect it would be on the process of drug absorption and not on drug elimination (renal excretion or hepatic metabolism). This assumption also informed our decision to use the 24-h predose concentration as the 24-h postdose concentration. If coencapsulation did reduce or delay C_{max}, this choice could bias (minimize) an effect on AUC. We believe this effect would be minimal, however, based on the median time to maximum concentrations we observed across all formulations of 2 h (IQR 1–2 h), the 24-h dosing intervals, and the half-lives of the ARVs. Acknowledging these limitations, the data support that we obtained good approximations of the PK characteristics of the various ARVs. In addition to the C_{max} and AUC values in Table 2, we have included a Supplementary Table S2 of the half-life values for the ARVs, all of which were in excellent agreement with literature values.

We did not use the traditional crossover design in this PK evaluation as the primary approach unless there were concerns in the initial analyses. The major reason behind this choice was based upon a number of other bioequivalence trials of coencapsulation of different drugs and the extensive experience with coencapsulation with the product used, indicating that the pretest likelihood of seeing a clinically relevant effect on PK was low.^{24,26} Indeed, most of the components in the ARVs tested demonstrated PK characteristics when coencapsulated, which were comparable to those found in the FDA-approved package inserts or in available literature. Although not as powerful as a classical crossover design, using historical reference values for comparison is an efficient approach to identify any signals as to whether coencapsulation affects PK. Where we saw differences, two (EVG and RPV) we believe were a food effect, and while the effect of coencapsulation on TDF and FTC (in the Truvada formulation) might also be a food effect, it could be a difference in study participants indicating some potential pitfalls in extrapolating PK characteristics from one population to another.

With a limited sample size and sampling data points, we needed to use an efficient statistical approach to avoid more parameter estimation and conserve statistical power. The one-sided independent two sample *t*-test is robust (i.e., not sensitive) to the normal distribution assumption for the C_{max} and AUC.⁴⁰ The two-sample *t*-test can still be used⁴¹ when the sample size is small, the two groups have unequal sample sizes and unequal variances, and the distribution is transformed into normal (e.g., the lognormal distributions). The

statistical power of using the independent two-sample *t*-test when sample size is small is still comparable among non-normal distributions (e.g., exponential, logistic) for evaluation of means or location parameters.⁴⁰ The one-sided test is used because the main purpose of the PK trials was to confirm that there was no significant reduction in values of PK parameters. In this case, a two-sided test will not be appropriate.

The demonstration of acceptable PK of several commonly used ARVs coencapsulated with an ingestible sensor creates a digital medication that can be used to measure and track a patients' ARV adherence in real-time.^{24,26,42} The findings from this study also provide some confidence that for those coencapsulated ARVs where PK characteristics did not meet our definition of no difference (e.g., EVG and RPV), the magnitude of differences in PK characteristics were unlikely to be clinically significant; our findings reinforce the recommendations that EVG and RPV must be administered with food. Collectively, the data from this study allow initiation of a planned randomized controlled trial to assess the feasibility, acceptability, and effectiveness of the ingestible sensor to investigate ARV adherence. Finally, the findings from this study will also enable researchers to conduct clinical trials with innovative behavioral interventions to improve adherence to ARV medications and enable clinicians to provide optimal care of HIV-infected individuals.

Acknowledgments

We thank all the individuals who participated in this pharmacokinetic trial of coencapsulated ARVs.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

This work was supported by grant R01-MH110056 from the National Institute of Mental Health (NIMH)/National Institute of Health (NIH).

Supplementary Material

Supplementary Table S1
Supplementary Table S2

References

- Hughes DA, Bagust A, Haycox A, Walley T: The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature. *Health Econ* 2001;10:601–615.
- Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ: Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: A pharmacy claims-based analysis. *Obstet Gynecol* 2000;95:167–173.
- Chesney MA: The elusive gold standard: Future perspectives for HIV adherence assessment and intervention. *J Acquir Immune Defic Syndr* 2006;43:S149–S155.
- Paterson DL, Swindells S, Mohr J, *et al.*: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med* 2000;133:21–30.
- Byrne C, Lim CL: The ingestible telemetric body core temperature sensor: A review of validity and exercise applications. *Br J Sports Med* 2007;41:126–133.
- Khoury MJ, Iademarco MF, Riley WT: Precision public health for the era of precision medicine. *Am J Prev Med* 2016;50:398.
- Lesho JC, Hogrefe AF: Ingestible size continuously transmitting temperature monitoring pill. Google Patents. 1989.
- Belluck P: *First Digital Pill Approved to Worries About Bio-medical 'Big Brother'*. New York Times, New York, 2017.
- Nair V, Grodzinski P, El-Zein N, Goronkin H: Ingestible electronic capsule. Google Patents, 2002.
- Browne S, Haubrich R, Moser K, *et al.*: Wirelessly observed therapy (WOT): A new paradigm in TB therapy monitoring. In: *Paper Presented at: Conference on Retroviruses and Opportunistic Infections*. Seattle, Washington 2015.
- Hafezi H, Robertson TL, Moon GD, Au-Yeung K-Y, Zdeblick MJ, Savage GM: An ingestible sensor for measuring medication adherence. *IEEE Trans Biomed Eng* 2015;62:99–109.
- Plowman RS, Peters-Strickland T, Savage GM: Digital medicines: Clinical Review on the Safety of Tablets with Sensors. *Expert Opin Drug Saf* 2018;17:849–852.
- Belknap R, Weis S, Brookens A, *et al.*: Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. *PLoS One* 2013;8:e53373.
- Klugman CM, Dunn LB, Schwartz J, Cohen IG: The ethics of smart pills and self-acting devices: Autonomy, truth-telling, and trust at the dawn of digital medicine. *Am J Bioeth* 2018;18:38–47.
- DiCarlo LA, Weinstein RL, Morimoto CB, *et al.*: Patient-centered home care using digital medicine and telemetric data for hypertension: Feasibility and acceptability of objective ambulatory assessment. *J Clin Hypertens* 2016;18:901–906.
- Peters-Strickland T, Pestreich L, Hatch A, *et al.*: Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole. *Neuropsychiatr Dis Treat* 2016;12:2587.
- Cruz A, Martinez B: Childhood tuberculosis in the United States: Shifting the focus to prevention. *Int J Tuberc Lung Dis* 2015;19:S50–S53.
- Eisenberger U, Wüthrich RP, Bock A, *et al.*: Medication adherence assessment: High accuracy of the new Ingestible Sensor System in kidney transplants. *Transplantation* 2013;96:245.
- Johannessen EA, Tang T-B, Wang L, *et al.*: An ingestible electronic pill for real time analytical measurements of the gastro-intestinal tract. In: *Micro Total Analysis Systems* (Baba Y, Shoji S, van den Berg A, eds.) Springer, Dordrecht, Netherlands, 2002.
- DiCarlo L, Moon G, Intondi A, *et al.*: A digital health solution for using and managing medications: Wirelessly observed therapy. *IEEE Pulse* 2012;3:23–26.
- Kalpouzos I, Giokas K, Koutsouris D: A survey on an ingestible sensor for evaluating medication adherence in elderly people. In: *Proceedings of the 8th ACM International Conference on Pervasive Technologies Related to Assistive Environments (PETRA '15)*. ACM, New York, NY, Article 10, 4 pages. DOI: <https://doi.org/10.1145/2769493.2769570>.
- Glenn T, Monteith S: New measures of mental state and behavior based on data collected from sensors, smartphones, and the Internet. *Current psychiatry reports* 2014;16:523.
- Mills EJ, Nachega JB, Buchan I, *et al.*: Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. *JAMA* 2006;296:679–690.

24. Ibrahim ME, Brooks KM, Castillo-Mancilla JR, *et al.*: Bioequivalence of tenofovir and emtricitabine after co-encapsulation with the Proteus ingestible sensor. *AIDS Res Hum Retroviruses* 2018;34:835–837.
25. Au-Yeung KY, Robertson T, Hafezi H, *et al.*: A networked system for self-management of drug therapy and wellness. In: *Paper Presented at: Wireless Health 2010*. 2010.
26. Browne S, Peloquin C, Santillo F, *et al.*: Digitizing medicines for remote capture of oral medication adherence using co-encapsulation. *Clin Pharmacol Ther* 2018;103:502–510.
27. Jones H, Chen Y, Gibson C, *et al.*: Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective. *Clin Pharmacol Ther* 2015;97:247–262.
28. Niazi SK: *Biosimilars and Interchangeable Biologics: Tactical Elements*. CRC Press, Boca Raton, FL, 2016.
29. Boxenbaum HG, Riegelman S, Elashoff RM: Statistical estimations in pharmacokinetics. *J Pharmacokinet Biopharm* 1974;2:123–148.
30. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK: Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. *J Clin Pharmacol* 1995;35:1174–1180.
31. Chow S-C, Liu J-P: Recent statistical developments in bioequivalence trials—A review of the FDA guidance. *Drug Inform J* 1994;28:851–864.
32. FDA U: *Guidance for Industry 35: Bioequivalence Guidance*. FDA, Rockville, MD, 2006.
33. Kakuda TN, Leopold L, Nijs S, *et al.*: Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial. *J Clin Pharmacol* 2014;54:563–573.
34. Stegemann S, Vishwanath S, Kumar R, *et al.*: Comparative human in-vivo study of an immediate release tablet over-encapsulated by gelatin and hydroxypropyl methyl cellulose capsules—impact of dissolution rate on bioequivalence. *Am Pharm Rev* 2015;11:38–45.
35. Fuseau E, Petricoul O, Sabin A, *et al.*: Effects of encapsulation on absorption of sumatriptan tablets: Data from healthy volunteers and patients during a migraine. *Clin Ther* 2001;23:242–251.
36. Podany AT, Scarsi KK, Fletcher CV: Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. *Clin Pharmacokinet* 2017;56:25–40.
37. Food and Drug Administration: *Genvoya (Package Insert)*. Gilead, Foster City, CA, 2016.
38. Chai PR, Pereira LM, Jambaulikar GD, *et al.*: Bioequivalence of tenofovir component of tenofovir/rilpivirine/emtricitabine in digital pills. *AIDS Res Hum Retroviruses* 2019;35:361–363.
39. Dickinson L, Khoo S, Back D: Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. *Curr Opin HIV AIDS* 2008;3:296–305.
40. Wellek S: *Testing Statistical Hypotheses of Equivalence and Noninferiority*. Chapman and Hall/CRC, Boca Raton, FL, 2010.
41. De Winter JC: Using the Student's t-test with extremely small sample sizes. *Pract Assess Res Eval* 2013;18:12.
42. Vallejos X, Wu C: Digital medicine: Innovative drug-device combination as new measure of medication adherence. *J Pharm Technol* 2017;33:137–139.
43. Gallant JE, Thompson M, DeJesus E, *et al.*: Antiviral activity, safety, and pharmacokinetics of bicitgravir as 10-day monotherapy in HIV-1-infected adults. *J Acquir Immune Defic Syndr* 2017;75:61–66.

Address correspondence to:

Honghu Liu, PhD

Public Health and Community Dentistry

Department of Medicine

Department of Biostatistics

University of California, Los Angeles (UCLA)

10833 Le Conte

Los Angeles, CA 90095-1668

E-mail: hhliu@mednet.ucla.edu